Regenerx Biopharmaceuticals Inc (RGRX) 0.4250 $RGRX
SeeThruEquity Initiates Coverage on RegeneRx Biopharmaceuticals, Inc. with a Price Target of $4.52
ACCESSWIRE - Wed Jul 08, 7:50AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) with a price target of $4.52.
Epidermolysis Bullosa - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxnlsl/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Fibrocell Science, Inc. - GlaxoSmithKline plc - InMed Pharmaceuticals Inc. - RegeneRx Biopharmaceuticals, Inc. - Scioderm, Inc. - Shire Plc - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jx...dermolysis
FCSC: 5.40 (+0.27), SHPG: 250.34 (+7.35), GSK: 42.45 (+0.65)
Epidermolysis Bullosa Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 25, 8:31PM CDT
The report "Epidermolysis Bullosa - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Epidermolysis Bullosa. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epidermolysi...eport.html .
SHPG: 250.34 (+7.35), GSK: 42.45 (+0.65)
Pulmonary Hypertension - Pipeline Review, H1 2015
M2 - Tue Jun 09, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7z25d/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Biolab Sanus Farmaceutica Ltda. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Celsion Corporation - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Ikaria Inc. - Insmed Incorporated - Ironwood Pharmaceuticals, Inc. - Lacer, S.A. - Longevity Biotech, Inc - LTT Bio-Pharma Co., Ltd. - Novartis AG - PhaseBio Pharmaceuticals, Inc. - Pluristem Therapeutics Inc. - Proteo, Inc. - Reata Pharmaceuticals, Inc. - RegeneRx Biopharmaceuticals, Inc. - Therametrics holding AG - Toray Industries, Inc. - United Therapeutics Corporation - Vectura Group plc - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/n7z25d/pulmonary
CYTK: 6.10 (+0.02), INSM: 23.89 (+0.06), PSTI: 2.40 (+0.03), UTHR: 171.57 (+3.88), CLDN: 1.26 (+0.01), LLY: 88.29 (+0.81), CLSN: 2.30 (+0.10), ASND: 19.38 (-0.22), IRWD: 11.44 (-0.06), GILD: 113.74 (+0.38), ARNA: 4.29 (+0.04), NVS: 103.22 (+3.20)
Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure
PR Newswire - Tue Jun 02, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced a peer-reviewed publication of the results of a recent cardiac stem cell clinical trial that demonstrates the potentially key role that Thymosin beta 4 (TB4) plays in the functional repair of cardiovascular disease. The REGENERATIVE-IHD trial is the largest, randomized, placebo-controlled clinical trial in the UK, to date, which was designed to investigate the use of autologous bone marrow-derived stem cells to improve cardiac function and symptoms in heart failure patients. As part of the trial, the authors studied a cohort of patients to determine if TB4 levels were affected by injection of stem cells and whether this had a correlation with clinical improvement. Serial plasma TB4 levels were obtained from patients and concentrations were measured in those who received stem cells and those who did not. According to the authors, "There was a significant increase in circulating levels of TB4 [in the stem cell-injected responder group only] 24 hours after intracardiac injection, which was directly associated with improvement in cardiac symptoms 6 months post-treatment."
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015
M2 - Wed May 27, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vmksm/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - EyeGate Pharmaceuticals, Inc. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kainos Medicine, Inc. - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Neuroptis Biotech - NovaBay Pharmaceuticals, Inc. - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - SIFI S.p.A For more information visit http://www.researchandmarkets.com/research/3v...njunctivit
OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), CLTX: 0.49 (-0.02)
RegeneRx to Present at 2 Investor Conferences
PR Newswire - Fri May 22, 9:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, chief executive officer of RegeneRx, is scheduled to present a corporate overview at two upcoming investor conferences.
Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology
PR Newswire - Fri May 22, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced a peer-reviewed publication of the results of the Company's 72-patient, placebo-controlled Phase II study evaluating RGN-259 (RegeneRx's preservative-free eye drops) for the treatment of dry eye patients using Ora Inc.'s controlled adverse environment (CAE®) model. The exploratory study was completed in late 2011, and the results, which were previously disseminated by the Company in a press release, identify the key efficacy targets for a larger, multi-center, Phase IIb/III U.S. clinical trial targeted for later this year. The trial will be sponsored by ReGenTree, LLC, a U.S. joint venture owned by RegeneRx and G-treeBNT.
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 0.28 (unch), CNCE: 15.71 (+0.27), ATHX: 1.14 (-0.01), KPTI: 25.57 (+0.24), CUR: 1.69 (-0.01)
Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function
PR Newswire - Fri May 08, 8:00AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that independent researchers have reported that diabetic mice treated long-term with Thymosin B4 (TB4) have significantly improved motor and sensory function in the sciatic nerve compared to the untreated animals and that TB4 protects the nerves and reverses neurological damage in diabetic neuropathy.
Penny Stocks Alerts for RegeneRx, Key Energy Services, Zynga, American Security Resources, Axxess Pharma, and Ecosciences
PR Newswire - Wed May 06, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: RegeneRx Biopharmaceuticals (OTCMKTS:RGRX), Key Energy Services (NYSE:KEG), Zynga (NASDAQ:ZNGA), American Security Resources (OTCMKTS:ARSC), Axxess Pharma (OTCMKTS:AXXE), and Ecosciences (OTCMKTS:ECEZ).
KEG: 1.37 (+0.07), ZNGA: 2.65 (unch)
Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing
PR Newswire - Mon May 04, 7:32AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced that an independent team of researchers from South Korea have reported that Thymosin B4 (TB4) plays an important role in accelerating the repair of second-degree dermal burn wounds, induced in an experimental mouse model, by promoting blood vessel formation and causing rapid vascular remodeling of damaged dermal tissue. The research found that the underlying mechanism of action is via actin cytoskeletal remodeling and the action of heat-shock proteins, which are induced when tissues or cells are exposed to stress. Heat shock proteins function to allow other proteins to assume their correct structures. The research also confirmed that remodeling of F-actin was regulated by TB4 by demonstrating its healing effects in the in vivo model.
RegeneRx awarded US PTO's notice of allowance for TB4 for healing and reversing cardiac tissue
M2 - Fri Apr 24, 5:17AM CDT
RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Thursday the receipt of a Notice of Allowance from the US Patent and Trademark Office (PTO) for its patent application claiming the administration of Thymosin beta 4 (TB4) to treat cardiac tissue.
RegeneRx Receives Notice of Allowance For U.S. Patent For Healing and Reversing Heart and Coronary Vessel Damage After A Heart Attack with TB4
PR Newswire - Thu Apr 23, 9:24AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application claiming the administration of Thymosin beta 4 (TB4) to treat cardiac tissue to heal and reverse heart and coronary vessel damage due to a heart attack, as well as to enhance the transition of immature heart cells into mature cells, among others.
RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.
PR Newswire - Thu Apr 16, 8:53AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year. Each of these eye disorders was being targeted by RegeneRx prior to entering into the joint venture.
/C O R R E C T I O N -- RegeneRx Biopharmaceuticals, Inc./
PR Newswire - Wed Apr 01, 8:40AM CDT
In the news release, RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea, issued 01-Apr-2015 by RegeneRx Biopharmaceuticals, Inc. over PR Newswire, we are advised by the company that there were changes to the second paragraph of the release. The complete, corrected release follows:
RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea
PR Newswire - Wed Apr 01, 7:36AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced that a new medical paper has been published describing the positive effects of Thymosin beta 4 (TB4) in patients with severe dry eye. The results met key efficacy objectives of the study and the physicians stated that statistically significant differences in both signs and symptoms of severe dry eye were seen at various time points throughout the study. Of particular note at day 56, the RGN-259-treated group had 35.1% reduction of ocular discomfort compared with vehicle control (P=0.0141), and 59.1% reduction of total corneal fluorescein staining compared with vehicle control (P = 0.0108). Other improvements seen in the RGN-259-treated patients included tear film breakup time and increased tear volume production.
RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments
PR Newswire - Thu Mar 26, 9:26AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx" today announced that it has received a patent acceptance notice from the Israeli patent office with claims for administering Thymosin beta 4 (TB4) to prevent or reduce tissue damage caused by an increase in blood flow, as is often the case when cardiac vessels are opened after a blockage causing a heart attack or in similar circumstances when treating stroke victims.
RegeneRx Receives Initial Payment for RGN-259 U.S. License to ReGenTree Joint Venture
PR Newswire - Wed Mar 25, 7:55AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company" has received an initial payment of $500,000 from ReGenTree, LLC, its U.S. joint venture with G-TreeBNT Co. Ltd., pursuant to a license of RGN-259 for ophthalmic indications to ReGenTree. RegeneRx expects to receive a second payment of $500,000 later this year upon enrollment of the first patient in a U.S. ophthalmic clinical trial sponsored by ReGenTree. ReGenTree is planning a Phase III trial for neurotrophic keratopathy (an orphan indication) and a Phase II trial for dry eye syndrome in the U.S., both to begin later this year.
RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Development of RGN-259/GBT-201
PR Newswire - Mon Mar 09, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" has been notified that its joint venture partner and licensee, G-treeBNT Co. Ltd., will receive $7.28 million USD to expand international development of its product candidate, RGN-259 (designated GBT-201).
SeeThruEquity Initiates Coverage on RegeneRx Biopharmaceuticals, Inc. with a Price Target of $4.52
ACCESSWIRE - Wed Jul 08, 7:50AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) with a price target of $4.52.
Epidermolysis Bullosa - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxnlsl/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Fibrocell Science, Inc. - GlaxoSmithKline plc - InMed Pharmaceuticals Inc. - RegeneRx Biopharmaceuticals, Inc. - Scioderm, Inc. - Shire Plc - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jx...dermolysis
FCSC: 5.40 (+0.27), SHPG: 250.34 (+7.35), GSK: 42.45 (+0.65)
Epidermolysis Bullosa Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 25, 8:31PM CDT
The report "Epidermolysis Bullosa - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Epidermolysis Bullosa. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epidermolysi...eport.html .
SHPG: 250.34 (+7.35), GSK: 42.45 (+0.65)
Pulmonary Hypertension - Pipeline Review, H1 2015
M2 - Tue Jun 09, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7z25d/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Biolab Sanus Farmaceutica Ltda. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Celsion Corporation - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Ikaria Inc. - Insmed Incorporated - Ironwood Pharmaceuticals, Inc. - Lacer, S.A. - Longevity Biotech, Inc - LTT Bio-Pharma Co., Ltd. - Novartis AG - PhaseBio Pharmaceuticals, Inc. - Pluristem Therapeutics Inc. - Proteo, Inc. - Reata Pharmaceuticals, Inc. - RegeneRx Biopharmaceuticals, Inc. - Therametrics holding AG - Toray Industries, Inc. - United Therapeutics Corporation - Vectura Group plc - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/n7z25d/pulmonary
CYTK: 6.10 (+0.02), INSM: 23.89 (+0.06), PSTI: 2.40 (+0.03), UTHR: 171.57 (+3.88), CLDN: 1.26 (+0.01), LLY: 88.29 (+0.81), CLSN: 2.30 (+0.10), ASND: 19.38 (-0.22), IRWD: 11.44 (-0.06), GILD: 113.74 (+0.38), ARNA: 4.29 (+0.04), NVS: 103.22 (+3.20)
Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure
PR Newswire - Tue Jun 02, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced a peer-reviewed publication of the results of a recent cardiac stem cell clinical trial that demonstrates the potentially key role that Thymosin beta 4 (TB4) plays in the functional repair of cardiovascular disease. The REGENERATIVE-IHD trial is the largest, randomized, placebo-controlled clinical trial in the UK, to date, which was designed to investigate the use of autologous bone marrow-derived stem cells to improve cardiac function and symptoms in heart failure patients. As part of the trial, the authors studied a cohort of patients to determine if TB4 levels were affected by injection of stem cells and whether this had a correlation with clinical improvement. Serial plasma TB4 levels were obtained from patients and concentrations were measured in those who received stem cells and those who did not. According to the authors, "There was a significant increase in circulating levels of TB4 [in the stem cell-injected responder group only] 24 hours after intracardiac injection, which was directly associated with improvement in cardiac symptoms 6 months post-treatment." Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015
M2 - Wed May 27, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vmksm/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - EyeGate Pharmaceuticals, Inc. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kainos Medicine, Inc. - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Neuroptis Biotech - NovaBay Pharmaceuticals, Inc. - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - SIFI S.p.A For more information visit http://www.researchandmarkets.com/research/3v...njunctivit
OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), CLTX: 0.49 (-0.02)
RegeneRx to Present at 2 Investor Conferences
PR Newswire - Fri May 22, 9:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, chief executive officer of RegeneRx, is scheduled to present a corporate overview at two upcoming investor conferences.
Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology
PR Newswire - Fri May 22, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced a peer-reviewed publication of the results of the Company's 72-patient, placebo-controlled Phase II study evaluating RGN-259 (RegeneRx's preservative-free eye drops) for the treatment of dry eye patients using Ora Inc.'s controlled adverse environment (CAE®) model. The exploratory study was completed in late 2011, and the results, which were previously disseminated by the Company in a press release, identify the key efficacy targets for a larger, multi-center, Phase IIb/III U.S. clinical trial targeted for later this year. The trial will be sponsored by ReGenTree, LLC, a U.S. joint venture owned by RegeneRx and G-treeBNT. Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.25 (-0.09), LPTN: 0.28 (unch), CNCE: 15.71 (+0.27), ATHX: 1.14 (-0.01), KPTI: 25.57 (+0.24), CUR: 1.69 (-0.01)
Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function
PR Newswire - Fri May 08, 8:00AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that independent researchers have reported that diabetic mice treated long-term with Thymosin B4 (TB4) have significantly improved motor and sensory function in the sciatic nerve compared to the untreated animals and that TB4 protects the nerves and reverses neurological damage in diabetic neuropathy.
Penny Stocks Alerts for RegeneRx, Key Energy Services, Zynga, American Security Resources, Axxess Pharma, and Ecosciences
PR Newswire - Wed May 06, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: RegeneRx Biopharmaceuticals (OTCMKTS:RGRX), Key Energy Services (NYSE:KEG), Zynga (NASDAQ:ZNGA), American Security Resources (OTCMKTS:ARSC), Axxess Pharma (OTCMKTS:AXXE), and Ecosciences (OTCMKTS:ECEZ).
KEG: 1.37 (+0.07), ZNGA: 2.65 (unch)
Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing
PR Newswire - Mon May 04, 7:32AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced that an independent team of researchers from South Korea have reported that Thymosin B4 (TB4) plays an important role in accelerating the repair of second-degree dermal burn wounds, induced in an experimental mouse model, by promoting blood vessel formation and causing rapid vascular remodeling of damaged dermal tissue. The research found that the underlying mechanism of action is via actin cytoskeletal remodeling and the action of heat-shock proteins, which are induced when tissues or cells are exposed to stress. Heat shock proteins function to allow other proteins to assume their correct structures. The research also confirmed that remodeling of F-actin was regulated by TB4 by demonstrating its healing effects in the in vivo model. RegeneRx awarded US PTO's notice of allowance for TB4 for healing and reversing cardiac tissue
M2 - Fri Apr 24, 5:17AM CDT
RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Thursday the receipt of a Notice of Allowance from the US Patent and Trademark Office (PTO) for its patent application claiming the administration of Thymosin beta 4 (TB4) to treat cardiac tissue.
RegeneRx Receives Notice of Allowance For U.S. Patent For Healing and Reversing Heart and Coronary Vessel Damage After A Heart Attack with TB4
PR Newswire - Thu Apr 23, 9:24AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application claiming the administration of Thymosin beta 4 (TB4) to treat cardiac tissue to heal and reverse heart and coronary vessel damage due to a heart attack, as well as to enhance the transition of immature heart cells into mature cells, among others. RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.
PR Newswire - Thu Apr 16, 8:53AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year. Each of these eye disorders was being targeted by RegeneRx prior to entering into the joint venture. /C O R R E C T I O N -- RegeneRx Biopharmaceuticals, Inc./
PR Newswire - Wed Apr 01, 8:40AM CDT
In the news release, RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea, issued 01-Apr-2015 by RegeneRx Biopharmaceuticals, Inc. over PR Newswire, we are advised by the company that there were changes to the second paragraph of the release. The complete, corrected release follows:
RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea
PR Newswire - Wed Apr 01, 7:36AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced that a new medical paper has been published describing the positive effects of Thymosin beta 4 (TB4) in patients with severe dry eye. The results met key efficacy objectives of the study and the physicians stated that statistically significant differences in both signs and symptoms of severe dry eye were seen at various time points throughout the study. Of particular note at day 56, the RGN-259-treated group had 35.1% reduction of ocular discomfort compared with vehicle control (P=0.0141), and 59.1% reduction of total corneal fluorescein staining compared with vehicle control (P = 0.0108). Other improvements seen in the RGN-259-treated patients included tear film breakup time and increased tear volume production. RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments
PR Newswire - Thu Mar 26, 9:26AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx"
today announced that it has received a patent acceptance notice from the Israeli patent office with claims for administering Thymosin beta 4 (TB4) to prevent or reduce tissue damage caused by an increase in blood flow, as is often the case when cardiac vessels are opened after a blockage causing a heart attack or in similar circumstances when treating stroke victims. RegeneRx Receives Initial Payment for RGN-259 U.S. License to ReGenTree Joint Venture
PR Newswire - Wed Mar 25, 7:55AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"
has received an initial payment of $500,000 from ReGenTree, LLC, its U.S. joint venture with G-TreeBNT Co. Ltd., pursuant to a license of RGN-259 for ophthalmic indications to ReGenTree. RegeneRx expects to receive a second payment of $500,000 later this year upon enrollment of the first patient in a U.S. ophthalmic clinical trial sponsored by ReGenTree. ReGenTree is planning a Phase III trial for neurotrophic keratopathy (an orphan indication) and a Phase II trial for dry eye syndrome in the U.S., both to begin later this year. RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Development of RGN-259/GBT-201
PR Newswire - Mon Mar 09, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"
has been notified that its joint venture partner and licensee, G-treeBNT Co. Ltd., will receive $7.28 million USD to expand international development of its product candidate, RGN-259 (designated GBT-201). 
